$NKTX
Nkarta Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024096186 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.585M
YoY Change -0.67%
% of Gross Profit
Research & Development $25.25M $23.13M
YoY Change 13.77% -7.93%
% of Gross Profit
Depreciation & Amortization $2.400M $2.300M
YoY Change 20.0% 187.5%
% of Gross Profit
Operating Expenses $33.79M $30.72M
YoY Change 15.36% -16.67%
Operating Profit -$33.79M -$30.72M
YoY Change 15.36% -16.67%
Interest Expense $5.724M
YoY Change 60.34%
% of Operating Profit
Other Income/Expense, Net $5.450M $5.722M
YoY Change 49.36% 60.24%
Pretax Income -$24.99M
YoY Change -24.92%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$28.34M -$24.99M
YoY Change 10.52% -24.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.39 -$0.34
Diluted Earnings Per Share -$0.39 -$0.34
COMMON SHARES
Basic Shares Outstanding 70.56M 70.47M
Diluted Shares Outstanding 73.56M 73.49M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $324.8M
YoY Change 15.7%
Cash & Equivalents $56.96M $120.4M
Short-Term Investments $204.4M
Other Short-Term Assets $6.978M
YoY Change 169.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $290.2M $331.8M
YoY Change 3.19% 15.72%
LONG-TERM ASSETS
Property, Plant & Equipment $76.23M $77.55M
YoY Change -1.87% 1.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $99.09M
YoY Change 429.08%
Other Assets $4.639M $3.533M
YoY Change 24.47% -3.63%
Total Long-Term Assets $241.9M $222.3M
YoY Change 94.01% 56.21%
TOTAL ASSETS
Total Short-Term Assets $290.2M $331.8M
Total Long-Term Assets $241.9M $222.3M
Total Assets $532.0M $554.1M
YoY Change 31.09% 29.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.937M $3.764M
YoY Change -54.79% 25.05%
Accrued Expenses $13.78M $11.57M
YoY Change -9.96% -34.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.47M $20.86M
YoY Change -12.37% -21.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $80.04M
YoY Change -5.22%
Total Long-Term Liabilities $80.04M
YoY Change -5.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.47M $20.86M
Total Long-Term Liabilities $80.04M
Total Liabilities $101.2M $100.9M
YoY Change -7.23% -9.15%
SHAREHOLDERS EQUITY
Retained Earnings -$518.3M -$489.9M
YoY Change 27.13% 28.25%
Common Stock $947.4M $943.4M
YoY Change 34.41% 34.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $430.9M $453.2M
YoY Change
Total Liabilities & Shareholders Equity $532.0M $554.1M
YoY Change 31.09% 29.15%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$28.34M -$24.99M
YoY Change 10.52% -24.92%
Depreciation, Depletion And Amortization $2.400M $2.300M
YoY Change 20.0% 187.5%
Cash From Operating Activities -$21.89M
YoY Change 0.56%
INVESTING ACTIVITIES
Capital Expenditures $2.354M
YoY Change -77.21%
Acquisitions
YoY Change
Other Investing Activities -$105.3M
YoY Change -1570.88%
Cash From Investing Activities -$107.6M
YoY Change 3294.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -368.0K
YoY Change -193.16%
NET CHANGE
Cash From Operating Activities -21.89M
Cash From Investing Activities -107.6M
Cash From Financing Activities -368.0K
Net Change In Cash -129.9M
YoY Change 429.09%
FREE CASH FLOW
Cash From Operating Activities -$21.89M
Capital Expenditures $2.354M
Free Cash Flow -$24.25M
YoY Change -24.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001787400
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39370
dei Entity Registrant Name
EntityRegistrantName
Nkarta, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4515206
dei Entity Address Address Line1
EntityAddressAddressLine1
1150 Veterans Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
925
dei Local Phone Number
LocalPhoneNumber
407-1049
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
NKTX
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70558754
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120398000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31040000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
204423000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
217149000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6978000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4882000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
331799000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
253071000
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
99086000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2743000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2743000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77551000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79326000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39374000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39949000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3533000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3796000
CY2024Q2 us-gaap Assets
Assets
554086000
CY2023Q4 us-gaap Assets
Assets
378885000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3764000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3665000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5532000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6069000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11565000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13596000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20861000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23330000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
80041000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82270000
CY2024Q2 us-gaap Liabilities
Liabilities
100902000
CY2023Q4 us-gaap Liabilities
Liabilities
105600000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
943385000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
708706000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-263000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-489945000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-435434000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
453184000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
273285000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
554086000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
378885000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23130000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25122000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48367000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51257000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7585000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11736000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15110000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19914000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
30715000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
36858000
us-gaap Operating Expenses
OperatingExpenses
63477000
us-gaap Operating Expenses
OperatingExpenses
71171000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30715000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-36858000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63477000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71171000
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
5724000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
3570000
us-gaap Investment Income Net
InvestmentIncomeNet
8970000
us-gaap Investment Income Net
InvestmentIncomeNet
7035000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5722000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3571000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8966000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7069000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-24993000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-33287000
us-gaap Net Income Loss
NetIncomeLoss
-54511000
us-gaap Net Income Loss
NetIncomeLoss
-64102000
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-136000
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-427000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-271000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
78000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25129000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33714000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54782000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64024000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73494523
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73494523
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48970391
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48970391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62088495
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62088495
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48946018
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48946018
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
273285000
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
15027000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
578000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4368000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-135000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-29518000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
473651000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
90000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
158000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4414000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-136000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-24993000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
453184000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
372207000
CY2023Q1 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
2000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4746000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
505000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30815000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
346646000
CY2023Q2 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
1000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
374000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4650000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-427000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-33287000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
317978000
us-gaap Profit Loss
ProfitLoss
-54511000
us-gaap Profit Loss
ProfitLoss
-64102000
us-gaap Share Based Compensation
ShareBasedCompensation
8782000
us-gaap Share Based Compensation
ShareBasedCompensation
9396000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4517000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1636000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3021000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4511000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
34000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
4100000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1154000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1100000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1833000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-663000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3345000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
7143000
nktx Increase Decrease In Accounts Payable And Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
-2143000
nktx Increase Decrease In Accounts Payable And Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
2078000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42531000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2529000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15151000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
214311000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
157486000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
130700000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
206395000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86140000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33758000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
667000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
158000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
374000
nktx Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
225073000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225898000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
396000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
89358000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8377000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33783000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40237000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
123141000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31860000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120398000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29117000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
2743000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2743000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123141000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31860000
nktx Non Cash Or Part Of Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities Resulting From New Leases
NonCashOrPartOfNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases
579000
nktx Non Cash Or Part Of Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities Resulting From New Leases
NonCashOrPartOfNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases
431000
nktx Non Cash Or Part Of Non Cash Stock Issuance Costs Included In Accrued And Other Current Liabilities
NonCashOrPartOfNonCashStockIssuanceCostsIncludedInAccruedAndOtherCurrentLiabilities
4000
nktx Noncash Or Part Noncash Acquisition Fixed Assets Acquired Included In Accounts Payable And Accrued And Other Current Liabilities
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
213000
nktx Noncash Or Part Noncash Acquisition Fixed Assets Acquired Included In Accounts Payable And Accrued And Other Current Liabilities
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
690000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-489900000
CY2024Q2 nktx Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
426700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies and clinical trial accruals, fair value of assets and liabilities, impairment of assets, leases, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.</span></p>
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-24993000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-33287000
us-gaap Net Income Loss
NetIncomeLoss
-54511000
us-gaap Net Income Loss
NetIncomeLoss
-64102000
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
70494492
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
48970457
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
60506061
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
48946131
CY2023Q2 nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-66
nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-113
CY2024Q2 nktx Weighted Average Of Common Stock To Be Issued Upon Exercise Of Pre Funded Warrants
WeightedAverageOfCommonStockToBeIssuedUponExerciseOfPreFundedWarrants
3000031
nktx Weighted Average Of Common Stock To Be Issued Upon Exercise Of Pre Funded Warrants
WeightedAverageOfCommonStockToBeIssuedUponExerciseOfPreFundedWarrants
1582434
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73494523
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73494523
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48970391
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48970391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62088495
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62088495
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48946018
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48946018
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9611804
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7474785
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
423600000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
273000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
423337000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
247892000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
69000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
77000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
247900000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
93761000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
91019000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16210000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11693000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77551000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79326000
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2300000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4500000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1600000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4918000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6722000
CY2024Q2 nktx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5532000
CY2023Q4 nktx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5845000
CY2024Q2 nktx Accrued Property And Equipment Liabilities Current
AccruedPropertyAndEquipmentLiabilitiesCurrent
243000
CY2023Q4 nktx Accrued Property And Equipment Liabilities Current
AccruedPropertyAndEquipmentLiabilitiesCurrent
174000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
872000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
855000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11565000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13596000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5300000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5500000
us-gaap Operating Lease Payments
OperatingLeasePayments
7600000
us-gaap Payments For Rent
PaymentsForRent
7300000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
2800000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
7800000
us-gaap Payments For Rent
PaymentsForRent
5000000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12Y
CY2023Q2 nktx Additional Tenant Improvement Allowances
AdditionalTenantImprovementAllowances
4400000
CY2023Q2 nktx Tenant Improvement Costs Equal Monthly Payments Annual Rate
TenantImprovementCostsEqualMonthlyPaymentsAnnualRate
0.085
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6554000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
13403000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
13462000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13912000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
14378000
CY2024Q2 nktx Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
72876000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
134585000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49012000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
85573000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5532000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
80041000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
85573000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
4100000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2024Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2023Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
nktx Contingency Loss Recorded
ContingencyLossRecorded
0
nktx Provision For Loss Contingency
ProvisionForLossContingency
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6716526
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.99
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8279000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2173650
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.15
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
143053
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
326848
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
21.74
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8420275
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5759000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4128806
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2700000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8420275
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5759000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4414000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4650000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8782000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9396000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 nktx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 nktx Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-096186-index-headers.html Edgar Link pending
0000950170-24-096186-index.html Edgar Link pending
0000950170-24-096186.txt Edgar Link pending
0000950170-24-096186-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktx-20240630.htm Edgar Link pending
nktx-20240630.xsd Edgar Link pending
nktx-ex10_1a.htm Edgar Link pending
nktx-ex10_1b.htm Edgar Link pending
nktx-ex31_1.htm Edgar Link pending
nktx-ex31_2.htm Edgar Link pending
nktx-ex32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
nktx-20240630_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending